Literature DB >> 27069144

Renieramycin M Sensitizes Anoikis-resistant H460 Lung Cancer Cells to Anoikis.

Natchanun Sirimangkalakitti1, Supakarn Chamni1, Khanit Suwanborirux2, Pithi Chanvorachote3.   

Abstract

BACKGROUND/AIM: Anoikis resistance plays a crucial role in the promotion of survival of circulating tumor cells. This study aimed to evaluate the mechanistic pathways of anoikis resistance in human lung cancer cells and test the possible therapeutic effect of renieramycin M (RM) from the sponge Xestospongia sp. in conversion of anoikis resistance.
MATERIALS AND METHODS: Anoikis-resistant H460 (AR_H460) lung cancer cells in a detached condition were treated with RM at subtoxic concentrations for 24 h. Cell viability, cell morphology, and expression of the proteins involved in survival and apoptotic pathways were determined.
RESULTS: Anoikis resistance in H460 cells is mediated through the up-regulation of survival and anti-apoptotic proteins, namely phosphorylated extracellular signal-regulated kinase (p-ERK), phosphorylated ATP-dependent tyrosine kinase (p-AKT), B-cell lymphoma-2 (BCL2), and myeloid cell leukemia-1 (MCL1). RM significantly reduced cell viability and inhibited spontaneous aggregation of AR_H460 cells. Western blot analysis revealed that RM suppressed the levels of survival proteins p-ERK and p-AKT and anti-apoptotic proteins BCL2 and MCL1.
CONCLUSION: RM is a potential anti-metastatic agent by sensitizing anoikis-resistant lung cancer cells to anoikis by the suppression of anoikis-resistance mechanisms. Copyright
© 2016 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

Entities:  

Keywords:  Renieramycin M; anoikis resistance; anoikis-sensitizing activity; anti-matastasis; lung cancer

Mesh:

Substances:

Year:  2016        PMID: 27069144

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  7 in total

1.  22-O-(N-Boc-L-glycine) ester of renieramycin M inhibits migratory activity and suppresses epithelial-mesenchymal transition in human lung cancer cells.

Authors:  Yamin Oo; Justin Quiel Lasam Nealiga; Khanit Suwanborirux; Supakarn Chamni; Gea Abigail Uy Ecoy; Varisa Pongrakhananon; Pithi Chanvorachote; Chatchai Chaotham
Journal:  J Nat Med       Date:  2021-07-21       Impact factor: 2.343

2.  5-O-(N-Boc-l-Alanine)-Renieramycin T Induces Cancer Stem Cell Apoptosis via Targeting Akt Signaling.

Authors:  Darinthip Suksamai; Satapat Racha; Nicharat Sriratanasak; Chatchai Chaotham; Kanokpol Aphicho; Aye Chan Khine Lin; Chaisak Chansriniyom; Khanit Suwanborirux; Supakarn Chamni; Pithi Chanvorachote
Journal:  Mar Drugs       Date:  2022-03-29       Impact factor: 6.085

Review 3.  Anoikis-Associated Lung Cancer Metastasis: Mechanisms and Therapies.

Authors:  Jing Wang; Zhijie Luo; Lizhu Lin; Xinbing Sui; Lili Yu; Cong Xu; Ruonan Zhang; Ziming Zhao; Qianru Zhu; Bo An; Qiao Wang; Bi Chen; Elaine Lai-Han Leung; Qibiao Wu
Journal:  Cancers (Basel)       Date:  2022-09-30       Impact factor: 6.575

4.  Avicequinone B sensitizes anoikis in human lung cancer cells.

Authors:  Arisara Prateep; Somruethai Sumkhemthong; Wiranpat Karnsomwan; Wanchai De-Eknamkul; Supakarn Chamni; Pithi Chanvorachote; Chatchai Chaotham
Journal:  J Biomed Sci       Date:  2018-04-09       Impact factor: 8.410

Review 5.  Marine Sponge Natural Products with Anticancer Potential: An Updated Review.

Authors:  Cinzia Calcabrini; Elena Catanzaro; Anupam Bishayee; Eleonora Turrini; Carmela Fimognari
Journal:  Mar Drugs       Date:  2017-10-13       Impact factor: 5.118

6.  Monascin accelerates anoikis in circulating tumor cells and prevents breast cancer metastasis.

Authors:  Kung-Yen Chen; Jui-An Lin; Han-Yun Yao; An-Chih Hsu; Yu-Ting Tai; Bing-Ying Ho
Journal:  Oncol Lett       Date:  2020-08-27       Impact factor: 2.967

7.  Chemistry of Renieramycins. Part 19: Semi-Syntheses of 22-O-Amino Ester and Hydroquinone 5-O-Amino Ester Derivatives of Renieramycin M and Their Cytotoxicity against Non-Small-Cell Lung Cancer Cell Lines.

Authors:  Supakarn Chamni; Natchanun Sirimangkalakitti; Pithi Chanvorachote; Khanit Suwanborirux; Naoki Saito
Journal:  Mar Drugs       Date:  2020-08-10       Impact factor: 5.118

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.